The Michael J. Fox Foundation's Parkinson's Progression Markers Initiative (PPMI) is an observational study to comprehensively evaluate Parkinson's disease (PD) patients using imaging, biologic sampling, clinical and behavioral assessments to identify biomarkers of PD progression. As part of this study, we obtained 4,756 whole blood samples from 1,570 subjects at baseline, 0.5, 1, 2, and 3 years from enrollment in the study. We isolated RNA and performed whole transcriptome sequencing in this longitudinal cohort. Here, we describe and quantify technical variability associated with this dataset through the use of pooled reference samples, including plate distribution, RNA quality, and outliers. This large, uniformly processed dataset is available to researchers at https://www.ppmi-info.org.

中文翻译：

---

帕金森氏病进展标记倡议（PPMI）中全血转录组分析的质量控制指标

迈克尔·J·福克斯基金会（Michael J. Fox Foundation）的帕金森氏病进展指标计划（PPMI）是一项观察性研究，旨在通过影像学，生物样本，临床和行为评估来评估帕金森氏病（PD）患者，以鉴定PD进展的生物标志物。作为这项研究的一部分，我们在基线，入选后0.5年，1、2和3年时，从基线的1,570名受试者中获得了4,756份全血样本。我们分离了RNA，并在此纵向队列中进行了完整的转录组测序。在这里，我们通过使用合并的参考样本来描述和量化与此数据集相关的技术变异性，包括板分布，RNA质量和离群值。研究人员可以在https://www.ppmi-info.org上获得经过统一处理的大型数据集。